Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PT003 · 1 trial · 1 indication
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 relative to baseline following chronic dosing (1 week).
| Arm | Type | Description |
|---|---|---|
| PT003 (Dose 1) | EXPERIMENTAL | PT003 MDI Dose 1 |
| PT003 (Dose 2) | EXPERIMENTAL | PT003 MDI Dose 2 |
| PT003 (Dose 3) | EXPERIMENTAL | PT003 MDI Dose 3 |
| PT003 (Dose 4) | EXPERIMENTAL | PT003 MDI Dose 4 |
| PT001 | EXPERIMENTAL | PT001 MDI |
| PT005 | EXPERIMENTAL | PT005 MDI |
| Name | Type | Description |
|---|---|---|
| PT003 | DRUG | PT003 MDI administered as two puffs BID for 7 days |
| PT001 | DRUG | PT001 MDI administered as two puffs BID for 7 days |
| PT005 | DRUG | PT005 MDI administered as two puffs BID for 7 days |
Key Inclusion Criteria: * Signed written informed consent * 40 - 80 years of age * Clinical history of COPD with airflow limitation that is not fully reversible * Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive ...
PT003 is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 2 clinical development and has completed one trial in this indication. The drug is being studied as a potential therapy for patients with COPD.
PT003 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is advancing this investigational drug through clinical development for the treatment of Chronic Obstructive Pulmonary Disease.
PT003 is currently in Phase 2 clinical development. It has completed one Phase 2 trial, which was a dose confirmation study. The drug is investigational and has not yet been approved by regulatory authorities for the treatment of Chronic Obstructive Pulmonary Disease.
PT003 has been studied in one clinical trial, identified as NCT01349816, titled "PT003 MDI Dose Confirmation Study." This Phase 2 trial was completed and enrolled 185 participants with Chronic Obstructive Pulmonary Disease in the United States. The trial was randomized, double-blind, and controlled.
PT003 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being developed by cbdMD, Inc. for the treatment of Chronic Obstructive Pulmonary Disease and is currently in Phase 2 clinical development.